Search PubMed⌕ Search

Biomedical subjects

W Rogowski

Publications and source records attributed to W Rogowski.

At least 19 recordsLinked to original sources
PubMed2000

[Which medical treatment can minimize late complications after pharmacologic treatment of unstable angina?].

UNLABELLED: Current pharmacological treatment of unstable coronary diseases has significantly reduced the rate of early and late complications. Aim of this study was to investigate the impact of in-hospital and ambulatory treatment on the occurrence of late complications in patients with unstable angina treated conservatively. The study group consisted of consecutive 79 patients hospitalized in our Department on the turn of years 1998-1999 (48 men--age 62 +/- 11 years), followed up by at least 1 year. We analyzed the administered agents on the first day of hospitalization: acetylsalicylic acid, heparin, nitroglycerin, beta-adrenergic agents, calcium channels blockers, statins and ACE inhibitors, as well these drugs prescribed for ambulatory management. At least one complication (recurrent hospitalization due to coronary artery disease, unstable angina pectoris, myocardial infarction, need for revascularization or death) occurred in 57 patients (72%) in a follow-up of 16 +/- 3 months. The following drugs significantly reduced rate of late complications (OR--odds ratio, CI--confidence interval, p--significance level):--intravenous heparin during hospitalization: OR = 0.22; CI = 0.12-0.42; p = 0.007;--acetylsalicylic acid administration during hospitalization: OR = 0.42; CI = 0.22-0.77; p = 0.03;--acetylsalicylic acid prescribed for ambulatory treatment: OR = 0.24; CI = 0.13-0.46; p = 0.05. CONCLUSIONS: Heparin and acetylsalicylic acid treatment seems to reduce the number of late complications in patients treated conservatively for the episode of unstable angina.

Adrenergic beta-Antagonists↗
PubMed1999

[Atrial fibrillation in mitral valve disease--risk factors].

UNLABELLED: Atrial fibrillation is frequently found in association with rheumatic mitral valve disease. However, the risk factors of atrial fibrillation have not been well established. The aim of this study was to assess risk factors of atrial fibrillation in patients with mitral valve disease. METHODS: The study group consisted of 141 patients (pts) with isolated mitral valve disease. Pts were divided into 3 groups (45 pts--mitral stenosis, 29 pts--mitral regurgitation, 67 pts--combined mitral valve disease). Mean age--52.5 years. Atrial fibrillation before operation was in 102 pts (72.3%). The clinical history of each patient was taken to obtain the patient's age, likely etiology of the valve lesion time of onset of atrial fibrillation. Echocardiografic and electrocardiografic records were performed in each patient. RESULTS: In all three groups of patients age and left atrial size were the most important factors of atrial fibrillation (atrial fibrillation was rare when left atrial dimension was below 40 mm). CONCLUSIONS: Atrial fibrillation was strongly associated with mitral stenosis and combined mitral disease. The most important factors of atrial fibrillation was age, left atrial dimension and hemodynamic class.

Adult↗
PubMed1997

[The role of potential duplication of time for the neoplastic cells in patients with head and neck cancer treated by radiation].

Proliferation potential of tumour cells is one of the most important features of malignant neoplasms. This factor can be assessed by measurement of the potential doubling time (Tpot). This method includes the single intravenous injection of thymidine analogue (iodo- or bromodeoxyuridine) with subsequent single biopsy of the tumour and simple calculation using flow cytometry data of the specimen. The preliminary results of clinical trials show that Tpot determined prior to treatment can serve as an independent prognostic factor in patients with head and neck cancer receiving conventional radiotherapy. This assay may also help to selected a subgroup of patients with high proliferation capacity for whom application of accelerated radiotherapy regimens may be advantageous. The aim of this paper is to describe the methodology of Tpot measurement and to review the clinical radiotherapy trials involving Tpot measurement.

Cell Movement↗
PubMed1994

A report comparing the use of tropisetron (Navoban), a 5-HT3 antagonist, with a standard antiemetic regimen of dexamethasone and metoclopramide in cisplatin-treated patients under conditions of severe emesis.

This report of a double-blind, randomized study performed to evaluate the comparative antiemetic efficacy of tropisetron (Navoban; Sandoz Pharma Ltd, Basel, Switzerland), a new 5-hydroxytryptamine receptor antagonist, focuses on treatment during stages of chemotherapy when nausea and vomiting are particularly severe. One hundred fifteen chemotherapy-naive patients with malignant disease were administered either tropisetron (n = 58) or a dexamethasone dose plus a metoclopramide dose (n = 57) during 5 days of two successive cycles of chemotherapy. Within the first 24 hours after receiving cisplatin-based chemotherapy, 76% of patients in the tropisetron group remained free of vomiting (with 59% of patients free of nausea) compared with 39% of patients free of vomiting in the conventionally treated group (30% of patients free of nausea). Improved control of emesis also was observed over 4 consecutive days of follow-up in the tropisetron group. The difference in incidence of nausea and vomiting between the patient groups was statistically significant (P < .05). The efficacy of tropisetron was well maintained during the second consecutive chemotherapy cycle; during the first 24 hours, 72% and 62% of patients remained free of vomiting and nausea, respectively. Tropisetron appears to be a highly effective, well tolerated, and simple to use antiemetic agent for patients receiving chemotherapy.

Adult↗